We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+11.03%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$10.6B
AUM Growth
+$1.17B
Cap. Flow
+$3.01B
Cap. Flow %
28.27%
Top 10 Hldgs %
22.3%
Holding
850
New
52
Increased
273
Reduced
342
Closed
48

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$96.9M
2
MRK icon
Merck
MRK
+$73.5M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$57.1M
4
ILMN icon
Illumina
ILMN
+$40.4M
5
TMO icon
Thermo Fisher Scientific
TMO
+$34.2M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$57.2M
2
IMMU
Immunomedics Inc
IMMU
+$51.7M
3
KMB icon
Kimberly-Clark
KMB
+$28.5M
4
BPMC
Blueprint Medicines
BPMC
+$26.5M
5
ANET icon
Arista Networks
ANET
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 35.77%
2 Technology 20.35%
3 Consumer Discretionary 9.49%
4 Communication Services 7.69%
5 Financials 7.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XYZ
426
Block Inc
XYZ
$49.2B
$2.98M 0.03%
18,318
-1,938
-10% -$274K
CAH icon
427
Cardinal Health
CAH
$53.2B
$2.96M 0.03%
63,137
-43,961
-41% -$2.26M
ENTA icon
428
Enanta Pharmaceuticals
ENTA
$378M
$2.93M 0.03%
+64,034
New +$3.1M
TRI icon
429
Thomson Reuters
TRI
$43.1B
$2.91M 0.03%
34,711
+20,994
+153% +$1.63M
KZR
430
DELISTED
Kezar Life Sciences
KZR
$2.9M 0.03%
60,000
– –
JNCE
431
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.88M 0.03%
+352,760
New +$2.19M
BSX icon
432
Boston Scientific
BSX
$68.4B
$2.87M 0.03%
75,200
-6,067
-7% -$234K
TDOC icon
433
Teladoc Health
TDOC
$1.2B
$2.81M 0.03%
12,822
+3,780
+42% +$800K
RMD icon
434
ResMed
RMD
$30.3B
$2.81M 0.03%
16,375
-30,510
-65% -$5.63M
BCE icon
435
BCE
BCE
$20.2B
$2.81M 0.03%
67,874
+1,868
+3% +$79K
CTRA
436
DELISTED
Coterra Energy
CTRA
$2.77M 0.03%
+159,798
New +$2.99M
MOS icon
437
The Mosaic Company
MOS
$7.24B
$2.75M 0.03%
150,682
+3,919
+3% +$63.8K
B
438
Barrick Mining
B
$63.2B
$2.72M 0.03%
97,243
+11,261
+13% +$321K
AVY icon
439
Avery Dennison
AVY
$13.4B
$2.7M 0.03%
21,131
-467
-2% -$55.1K
LNC icon
440
Lincoln National
LNC
$8.8B
$2.69M 0.03%
85,721
+5,043
+6% +$180K
GWW icon
441
W.W. Grainger
GWW
$64B
$2.64M 0.02%
7,411
-332
-4% -$114K
ETR icon
442
Entergy
ETR
$50.4B
$2.6M 0.02%
52,806
-2,422
-4% -$120K
MASI
443
DELISTED
Masimo
MASI
$2.6M 0.02%
11,000
+2,000
+22% +$448K
WBA
444
DELISTED
Walgreens Boots Alliance
WBA
$2.59M 0.02%
72,064
+7,376
+11% +$288K
SCHW
445
Charles Schwab
SCHW
$181B
$2.56M 0.02%
70,778
-3,251
-4% -$113K
KEY icon
446
KeyCorp
KEY
$24.2B
$2.56M 0.02%
214,510
-1,459
-0.7% -$17.8K
AMRN
447
Amarin Corp
AMRN
$298M
$2.55M 0.02%
30,300
– –
ALLO icon
448
Allogene Therapeutics
ALLO
$680M
$2.51M 0.02%
66,561
-1,366
-2% -$51.5K
OC icon
449
Owens Corning
OC
$11.2B
$2.49M 0.02%
36,134
-1,805
-5% -$116K
RHI icon
450
Robert Half
RHI
$3.81B
$2.47M 0.02%
46,646
-24,905
-35% -$1.33M
16 17
18
19 20

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Candriam SCA's Q3 2020 Portfolio in Review

As of Q3 2020, Candriam SCA held 850 positions worth $10.6B, up 12% from $9.47B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Candriam SCA deployed $3.01B of net new capital in Q3 2020, opening 52 new positions and adding to 273 existing holdings. Its largest new stake was VIVINT SOLAR, INC.: 840,936 shares worth $35.6M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 35% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Apple, an estimated $57.2M trimmed.

  • Candriam SCA's largest Q3 2020 buy was VIVINT SOLAR, INC.: 840,936 shares worth $35.6M.
  • Candriam SCA added most to Amgen in Q3 2020, an estimated $96.9M increase.
  • Candriam SCA's biggest Q3 2020 reduction was Apple, cutting an estimated $57.2M.
  • Candriam SCA fully exited G1 Therapeutics, Inc. Common Stock in Q3 2020, selling an estimated $21.1M.
  • Candriam SCA's ten largest holdings make up 22% of its $10.6B portfolio in Q3 2020.
  • Candriam SCA opened 52 new positions and closed 48 in Q3 2020.
  • Candriam SCA's portfolio value rose 12% quarter-over-quarter to $10.6B.

Based on Candriam SCA's 13F filing for Q3 2020, filed 19 Oct 2020.